Organization
Harbor-UCLA Medical Center
5 abstracts
Abstract
A phase-1 dose escalation and expansion study of EP0031, a next-generation selective RET inhibitor (SRI), in patients with SRI-naïve or pretreated advanced RET-altered NSCLC and other tumors.Org: Harbor-UCLA Medical Center, Department of Medical Oncology, University of Kentucky, Markey Cancer Center, University College London Cancer Institute, University College London Hospital NHS Trust,
Abstract
Immune checkpoint inhibitor effects on male reproduction.Org: Harbor-UCLA Medical Center, Torrance, CanSino Biologics, The Lundquist Institute, City of Hope Comprehensive Cancer Center,
Abstract
AGE, SEROPOSITIVITY AND INFLAMMATION DETERMINE RISK VERSUS BENEFIT OF ENDOGENOUS ESTROGENS ON CORONARY ATHEROSCLEROSIS IN RHEUMATOID ARTHRITISOrg: Harbor-UCLA Medical Center, The Lundquist Institute, University of Parma,
Abstract
ABDOMINAL OBESITY MAY CONFOUND THE ACCURACY OF CARDIOVASCULAR RISK PREDICTION IN RHEUMATOID ARTHRITIS; CAN CORONARY ATHEROSCLEROSIS IMAGING AND BIOMARKERS HELP?Org: Harbor-UCLA Medical Center, The Lundquist Institute,
Abstract
ATP-BINDING CASSETTE G1 MEMBRANE TRANSPORTER-MEDIATED CHOLESTEROL EFFLUX CAPACITY INFLUENCES CORONARY ATHEROSCLEROSIS AND CARDIOVASCULAR RISK IN RHEUMATOID ARTHRITISOrg: Harbor-UCLA Medical Center, The Lundquist Institute, Rheumatology, Torrance, United States of America, University of Parma - Parco Area delle Scienze, Internal Medicine, Parma, Italy,